Nanoparticles Fight Lung Cancer & Cystic Fibrosis
A groundbreaking nanoparticle drug delivery system is revolutionizing the treatment of lung diseases. This innovative approach, highlighted by researchers from Oregon State University, effectively transports genetic medicines directly to the lungs. The latest study reveals this targeted delivery method shows real promise in combating both lung cancer and cystic fibrosis. the new system utilizes specially designed nanoparticles to safely and efficiently deliver messenger RNA and gene-editing tools, offering hope for patients. News Directory 3 has the vital details on how this technology could transform respiratory care and beyond.Discover what’s next as researchers refine this nanoparticle drug delivery and expand its potential.
Nanoparticle Drug Delivery System Targets Lung Disease
Updated June 13, 2025
A novel drug delivery system using nanoparticles to transport genetic therapies directly to the lungs has been developed, offering new hope for treating respiratory diseases. The system shows promise for conditions such as lung cancer and cystic fibrosis,researchers report.
The research, spearheaded by Gaurav Sahay at Oregon State University (OSU) in collaboration with oregon Health & Science University (OHSU) and the University of Helsinki, involved creating and testing over 150 materials.The team discovered a nanoparticle capable of safely and effectively delivering messenger RNA and gene-editing tools to lung cells.
Mouse studies demonstrated the treatmentS effectiveness in slowing lung cancer growth and improving lung function impaired by cystic fibrosis,a genetic disorder. The scientists also devised a chemical strategy for creating a library of lung-targeting lipids for use in nanocarriers.
according to Sahay, these materials form the basis for the new drug delivery system and can be tailored to target various organs. The streamlined synthesis simplifies the design of future therapies for a wide range of diseases, he added. The study highlights the potential of targeted delivery for genetic medicines, enabling both immune system activation to combat cancer and restoration of function in genetic lung disease, all without significant side effects.
“Our long-term goal is to create safer, more effective treatments by delivering the right genetic tools to the right place,” Sahay said. “this is a major step in that direction.”
K. Yu Vlasova, D.K.Sahel, Namratha Turuvekere Vittala Murthy, Milan Gautam and Antony Jozic from OSU were among the co-authors of the Nature Communications paper. Murthy,Jonas Renner,Gautam,Emily Bodi and Jozic also collaborated with Sahay on the other study,which appeared in the Journal of the american Chemical Society.
What’s next
Researchers plan to further refine the nanoparticle drug delivery system and conduct additional studies to assess its long-term efficacy and safety in treating lung diseases.